Work

071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program

Year: 2018

Type: article

Source: Journal of Neurology Neurosurgery & Psychiatry

DOI: 10.1136/jnnp-2018-anzan.70

Authors: Lana Zhovtis Ryerson, John Foley, Ih Chang, Ilya Kister, Gary Cutter, Ryan Metzger, Judith D Goldberg, Xiaochun Li, Evan Riddle, Karen Smirnakis, Bei Yu, Zheng Ren, Christophe Hotermans, Pei-Ran Ho, Nolan Campbell

Institutions: NYU Langone Health, New York University, Rocky Mountain Multiple Sclerosis Clinic, Biogen (United States), University of Alabama, University of Alabama at Birmingham

Language: English

Topic: Polyomavirus and related diseases

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2804085895

FWCI: 0.59

Cites:

Cited by: 7

Related to: 10